{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:13:01Z","timestamp":1784027581621,"version":"3.55.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.critrevonc.2024.104347","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T12:57:58Z","timestamp":1712408278000},"page":"104347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A systematic review and meta-analysis of the effectiveness of primary thromboprophylaxis in acute lymphoblastic leukemia during early-phase therapy including asparaginase or its prolonged form"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-0626","authenticated-orcid":false,"given":"Zhongbo","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogindra","family":"Persaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.critrevonc.2024.104347_bib1","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1182\/blood-2009-07-231084","article-title":"The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase","volume":"114","author":"Abbott","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104347_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-159-4-201308200-00008","article-title":"Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review","volume":"159","author":"Adam","year":"2013","journal-title":"Ann. Intern Med."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2024.104347_bib3","first-page":"2397","article-title":"Thromboprophylaxis with fixed dose, 1mg\/kg\/day, low molecular weight heparin in adults yndergoing induction with asparaginase for acute lymphoblastic leukemia. Results of a single institution cohort study","volume":"130","author":"Al Rabadi","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104347_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.18397","article-title":"A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management","volume":"199","author":"Andersson","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104347_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41375-021-01383-2","article-title":"Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia","volume":"36","author":"Andres-Jensen","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104347_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29581","article-title":"Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: results from Dana-Farber Cancer Institute ALL Consortium trial 05-001","volume":"69","author":"Athale","year":"2022","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.critrevonc.2024.104347_bib7","doi-asserted-by":"crossref","unstructured":"J.N. Barreto, K.B. McCullough, C.S. Peskey, R.A. Dierkhising, K.C. Mara, M.A. Elliott, D.A. Gastineau, A. Al-Kali, N. Gangat, L. Letendre, W.J. Hogan, M.R. Litzow, M.M. Patnaik, Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy<sup\/>, Leuk Lymphoma 58(11) (2017) 2588-2597.","DOI":"10.1080\/10428194.2017.1312384"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104347_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102759","article-title":"Venous thromboembolism and its risk factors in children with acute lymphoblastic leukemia in israel: a population-based study","volume":"12","author":"Barzilai-Birenboim","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104347_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ajh.20230","article-title":"Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia","volume":"77","author":"Beinart","year":"2004","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104347_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"Brandao","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104347_bib11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/10428194.2018.1519811","article-title":"Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia","volume":"60","author":"Chen","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104347_bib12","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ajh.24130","article-title":"Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience","volume":"90","author":"Couturier","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104347_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.seminhematol.2007.02.004","article-title":"Epidemiology and risk factors for venous thrombosis","volume":"44","author":"Cushman","year":"2007","journal-title":"Semin Hematol."},{"key":"10.1016\/j.critrevonc.2024.104347_bib14","article-title":"Antithrombin deficiency and venous thrombo-embolic events in children with acute lymphoblastic leukemia receiving L-asparaginase","author":"Dementieva","year":"2020","journal-title":"Pedia Blood Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104347_bib15","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1182\/blood.V91.12.4561","article-title":"Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin","volume":"91","author":"Edmunds","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104347_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00001721-200107000-00005","article-title":"Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia","volume":"12","author":"Elhasid","year":"2001","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104347_bib17","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/10428190410001693588","article-title":"Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin","volume":"45","author":"Elliott","year":"2004","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104347_bib18","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3109\/10428194.2016.1165815","article-title":"An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events","volume":"57","author":"Farrell","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2024.104347_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2020.02.015","article-title":"Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches?","volume":"188","author":"Fulcher","year":"2020","journal-title":"Thromb. Res"},{"key":"10.1016\/j.critrevonc.2024.104347_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106368","article-title":"Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study","volume":"94","author":"George","year":"2020","journal-title":"Leuk. Res"},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104347_bib21","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.2217\/fon.15.114","article-title":"L-asparaginase and venous thromboembolism in acute lymphocytic leukemia","volume":"11","author":"Goyal","year":"2015","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104347_bib22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104347_bib23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11239-017-1597-7","article-title":"The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia","volume":"45","author":"Grace","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104347_bib24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104347_bib25","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood-2018-99-116744","article-title":"Decreae of asparaginase induced thrombotic events with antithrombin III monitoring and repletion","author":"Grose","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104347_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2141.1990.tb06336.x","article-title":"Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo","volume":"74","author":"Gugliotta","year":"1990","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104347_bib27","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2021-148945","article-title":"Thrombosis prophylaxis with Apixaban in patients treated with asparaginase","volume":"138","author":"Gundabolu","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104347_bib28","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children's oncology group","volume":"38","author":"Gupta","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104347_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104347_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ajh.2830470302","article-title":"Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase","volume":"47","author":"Halton","year":"1994","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104347_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2010.04.013","article-title":"Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment","volume":"126","author":"Harlev","year":"2010","journal-title":"Thromb. Res"},{"key":"10.1016\/j.critrevonc.2024.104347_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104347_bib33","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3324\/haematol.12948","article-title":"Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study","volume":"93","author":"Hunault-Berger","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104347_bib34","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.thromres.2015.10.034","article-title":"Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults","volume":"136","author":"Ignjatovic","year":"2015","journal-title":"Thromb. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104347_bib35","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.clinthera.2007.11.015","article-title":"Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients","volume":"29","author":"Kanaan","year":"2007","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104347_bib36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00280-021-04252-y","article-title":"Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens","volume":"87","author":"Kashanian","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.critrevonc.2024.104347_bib37","first-page":"e109","article-title":"Venous Thrombosis in Children with Acute Lymphoblastic Leukemia Treated on DCOG ALL-9 and ALL-10 Protocols: The Effect of Fresh Frozen Plasma","author":"Klaassen","year":"2019","journal-title":"TH Open 3(2"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104347_bib38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12887-017-0877-x","article-title":"TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial","volume":"17","author":"Klaassen","year":"2017","journal-title":"BMC Pedia"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104347_bib39","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2141.2006.06209.x","article-title":"Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study","volume":"134","author":"Kuhle","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"26","key":"10.1016\/j.critrevonc.2024.104347_bib40","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104347_bib41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH12-11-0845","article-title":"Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation","volume":"109","author":"Lauw","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104347_bib42","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1080\/10428194.2022.2098288","article-title":"Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population","volume":"63","author":"Lee","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104347_bib43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/jth.13265","article-title":"The influence of corticosteroids on hemostasis in healthy subjects","volume":"14","author":"Majoor","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104347_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"E.I.-J.P. Investigators, Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104347_bib45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/08880010290108744","article-title":"Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase","volume":"19","author":"Matsuzaki","year":"2002","journal-title":"Pedia Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104347_bib46","first-page":"209","article-title":"A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase","volume":"76","author":"Mattioli Belmonte","year":"1991","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104347_bib47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00001721-199402000-00004","article-title":"Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study","volume":"5","author":"Mazzucconi","year":"1994","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104347_bib48","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/pbc.21222","article-title":"Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia","volume":"50","author":"Meister","year":"2008","journal-title":"Pedia Blood Cancer"},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104347_bib49","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1182\/blood-2010-01-263012","article-title":"Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study","volume":"115","author":"Mitchell","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104347_bib50","first-page":"235","article-title":"Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study","volume":"90","author":"Mitchell","year":"2003","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104347_bib51","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.11042","volume":"97","author":"Mitchell","year":"2003","journal-title":"Cancer"},{"issue":"2 Suppl","key":"10.1016\/j.critrevonc.2024.104347_bib52","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of\u00a0chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104347_bib53","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104347_bib54","first-page":"451","article-title":"Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy","volume":"80","author":"Nowak-Gottl","year":"1995","journal-title":"Haematologica"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2024.104347_bib55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0609.1996.tb00290.x","article-title":"Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children","volume":"56","author":"Nowak-Gottl","year":"1996","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104347_bib56","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1055\/s-0039-1679938","article-title":"PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)-rationale and design","volume":"119","author":"O'Brien","year":"2019","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104347_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"P.-A. investigators, Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","volume":"11","author":"O'Brien","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2024.104347_bib58","first-page":"328","article-title":"Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study","author":"Orvain","year":"2020","journal-title":"Blood 136(3"},{"key":"10.1016\/j.critrevonc.2024.104347_bib59","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ 372"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104347_bib60","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1517\/14712598.2010.495713","article-title":"Pharmacology and clinical applications of human recombinant antithrombin","volume":"10","author":"Pal","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104347_bib61","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1055\/s-0039-1697027","article-title":"Effectiveness and Safety of Primary Thromboprophylaxis in Children with Cancer: A Systematic Review of the Literature and Network Meta-Analysis","volume":"119","author":"Pelland-Marcotte","year":"2019","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104347_bib62","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2018-06-820746","article-title":"Treatment of bleeding complications in patients on anticoagulant therapy","volume":"133","author":"Piran","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104347_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000204081","article-title":"L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy","volume":"93","author":"Pogliani","year":"1995","journal-title":"Acta Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104347_bib64","first-page":"120","article-title":"Risk factors for venous and arterial thrombosis","volume":"9","author":"Previtali","year":"2011","journal-title":"Blood Transfus."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104347_bib65","article-title":"Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia","author":"Rank","year":"2020","journal-title":"Cochrane Database Syst. Rev. 10"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104347_bib66","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104347_bib67","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/MBC.0b013e328363b147","article-title":"Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia","volume":"24","author":"Ranta","year":"2013","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2024.104347_bib68","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood-2023-180037","volume":"142","author":"Rodriguez","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104347_bib69","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/jth.15699","article-title":"Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013","volume":"20","author":"Ruiz-Llobet","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104347_bib70","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Subcommittee on Control of Anticoagulation of the, T. Standardization Committee of the International Society on, Haemostasis, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104347_bib71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104347_bib72","unstructured":"H. Schunemann, J. Higgins, G. Vist, P. Glasziou, E. Akl, N. Skoetz, G. Guyatt, Chapter 14: Completing \u02bbSummary of findings\u02bc tables and grading the certainty of the evidence, Available from www.training.cochrane.org\/handbook., Cochrane, 2023."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104347_bib73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0377-1237(17)30571-3","article-title":"Low Molecular Weight Heparins","volume":"54","author":"Sharma","year":"1998","journal-title":"Med J. Armed Forces India"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104347_bib74","doi-asserted-by":"crossref","DOI":"10.3747\/co.23.3077","article-title":"Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia","volume":"23","author":"Sibai","year":"2016","journal-title":"Curr. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104347_bib75","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.16695","article-title":"Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy","volume":"191","author":"Sibai","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104347_bib76","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104347_bib77","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.leu.2405051","article-title":"Fresh frozen plasma contains free asparagine and may replace the plasma asparagine pool during L-asparaginase therapy","volume":"22","author":"Steiner","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104347_bib78","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic Therapy for VTE Disease: Second Update of\u00a0the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2024.104347_bib79","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ijlh.12531","article-title":"Developmental hemostasis: laboratory and clinical implications","volume":"38","author":"Toulon","year":"2016","journal-title":"Int J. Lab Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104347_bib80","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2012.290","article-title":"The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia","volume":"27","author":"Truelove","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104347_bib81","article-title":"Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians","author":"Tun","year":"2013","journal-title":"Thrombosis 2013"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104347_bib82","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/j.1538-7836.2010.04034.x","article-title":"Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors","volume":"8","author":"van Zaane","year":"2010","journal-title":"J. Thromb. Haemost."},{"issue":"31","key":"10.1016\/j.critrevonc.2024.104347_bib83","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104347_bib84","unstructured":"Wells, G.A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M. , Tugwell, P. (2010). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104347_bib85","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jth.14671","article-title":"The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on Hemostasis and Malignancy of the ISTH","volume":"18","author":"Zwicker","year":"2020","journal-title":"J. Thromb. Haemost."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T20:44:27Z","timestamp":1731703467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":85,"alternative-id":["S1040842824000908"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104347","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of the effectiveness of primary thromboprophylaxis in acute lymphoblastic leukemia during early-phase therapy including asparaginase or its prolonged form","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104347"}}